Also from this source

You just read:

PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate

News provided by

Lucerne Biosciences, LLC

Jun 13, 2015, 07:00 ET